Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co.
Looking at options history for Eli Lilly and Co (NYSE:LLY) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $150,700 and 8, calls, for a total amount of $372,495.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $1000.0 for Eli Lilly and Co, spanning the last three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly and Co's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly and Co's substantial trades, within a strike price spectrum from $380.0 to $1000.0 over the preceding 30 days.
Eli Lilly and Co Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly and Co, we pivot to a closer look at the company's own performance.
Where Is Eli Lilly and Co Standing Right Now?
- Trading volume stands at 43,681, with LLY's price down by 0.0%, positioned at $890.11.
- RSI indicators show the stock to be may be overbought.
- Earnings announcement expected in 42 days.
What The Experts Say On Eli Lilly and Co
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $948.4.
- Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Eli Lilly and Co, targeting a price of $957.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $885.
- Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Eli Lilly and Co with a target price of $1000.
- An analyst from Jefferies has decided to maintain their Buy rating on Eli Lilly and Co, which currently sits at a price target of $1015.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $885.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly and Co options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
